LNTH
NASDAQLantheus Holdings Inc.
Price$100.52-0.78 (-0.77%)
01:45 PM07:45 PM
News · 26 weeks51+143%
2025-12-142026-06-07
Mix2990d
- Insider12(41%)
- Other9(31%)
- SEC Filings6(21%)
- Earnings2(7%)
Latest news
25 items- INSIDERDirector Ber Gerard covered exercise/tax liability with 381 shares, decreasing direct ownership by 1% to 27,118 units (SEC Form 4)4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
- INSIDERExecutive Chair and CEO Heino Mary Anne covered exercise/tax liability with 1,227 shares, decreasing direct ownership by 0.38% to 321,897 units (SEC Form 4)4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
- PRLantheus to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceBEDFORD, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced John Wiggins, Vice President, External Manufacturing, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference at 8:40 a.m. ET on Tuesday, June 9. To access the live webcast of the presentations, please visit the Investors section of the Company's website at www.lantheus.com. A replay of the webcasts will be available on the Company's website for at least 30 days followi
- PRLantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI's Image of the YearBEDFORD, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that an image generated using LNTH-2513 (18F-GP1) PET/CT was awarded SNMMI's Image of the Year at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting in Los Angeles, California. The recognition was presented in connection with investigator-initiated trial results evaluating LNTH-2513 PET/CT for the detection of acute lower-extremity deep vein thrombosis (DVT) in symptomatic patients. "These resu
- SECSEC Form SD filed by Lantheus Holdings Inc.SD - Lantheus Holdings, Inc. (0001521036) (Filer)
- PRLantheus to Present at the William Blair 46th Annual Growth Stock ConferenceBEDFORD, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced John Wiggins, Vice President, External Manufacturing, will participate in a fireside chat at the William Blair 46th Annual Growth Stock Conference at 12:10 p.m. ET on Wednesday, June 3. To access the live webcast of the presentations, please visit the Investors section of the Company's website at www.lantheus.com. A replay of the webcasts will be available on the Company's website for at least 30 days following
- PRLantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual MeetingBEDFORD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced new radiodiagnostic data to be presented at the 2026 Society of Nuclear Medicine and Medical Imaging (SNMMI) Annual Meeting, taking place May 30 – June 2, 2026 in Los Angeles, CA. Presentation details are as follows: Date & Time: Monday, June 1, 2026, 10:30 am – 11:15 am PT Session Type: PosterSession Title: Oncology Clinical Diagnosis and Therapy Scientific Session Session Number: MTA06 – Screen 29Title: Impact of PSMA-PET wi
- PRLantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingBEDFORD, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced data to be featured at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026 in Chicago, IL. Presentation details are as follows: Date & Time: Monday, June 1 Session Type: Poster Session Title: Sarcoma Poster Number: 376b Title: A phase 1/2, multi-center, open-label study to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary anti-neoplasti
- INSIDERDirector Mchugh Julie was granted 4,137 shares, increasing direct ownership by 16% to 30,099 units (SEC Form 4)4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
- INSIDERDirector Morrow Phuong Khanh was granted 4,137 shares, increasing direct ownership by 133% to 7,237 units (SEC Form 4)4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
- INSIDERDirector Maeusli Heinz Christoph was granted 4,137 shares, increasing direct ownership by 16% to 30,014 units (SEC Form 4)4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
- INSIDERDirector Pruden Gary J was granted 4,137 shares, increasing direct ownership by 163% to 6,674 units (SEC Form 4)4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
- INSIDERDirector Leno Sam R was granted 4,137 shares, increasing direct ownership by 7% to 67,246 units (SEC Form 4)4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
- INSIDERDirector Baylor-Henry Minnie was granted 4,137 shares, increasing direct ownership by 42% to 14,018 units (SEC Form 4)4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
- INSIDERDirector Ber Gerard was granted 4,137 shares, increasing direct ownership by 18% to 27,499 units (SEC Form 4)4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
- INSIDERDirector Thrall James H was granted 4,137 shares, increasing direct ownership by 12% to 39,881 units (SEC Form 4)4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
- INSIDERDirector Eastland Julia Marie was granted 4,137 shares, increasing direct ownership by 107% to 8,019 units (SEC Form 4)4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.SCHEDULE 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)
- SECSEC Form 10-Q filed by Lantheus Holdings Inc.10-Q - Lantheus Holdings, Inc. (0001521036) (Filer)
- SECLantheus Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Lantheus Holdings, Inc. (0001521036) (Filer)
- PRLantheus Reports First Quarter 2026 Financial Results and Provides Business UpdateStrong start to the year with worldwide revenue of $377.3 million in the first quarter 2026GAAP fully diluted earnings per share of $1.80, compared to $1.02 in the first quarter of 2025Adjusted fully diluted earnings per share of $1.46, compared to $1.53 in the first quarter of 2025FDA approves PYLARIFY TruVuTM (piflufolastat F18); phased geographic launch planned to begin in the fourth quarter of 2026FDA tentative approval for Lutetium Lu 177 Dotatate (PNT2003); expected to be the first radioequivalent for the treatment of gastroenteropancreatic neuroendocrine tumorsReaffirmed previously issued corporate guidance for full year 2026 revenue and adjusted fully diluted earnings per share BEDF
- SECLantheus Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders8-K - Lantheus Holdings, Inc. (0001521036) (Filer)
- PRLantheus to Host First Quarter 2026 Earnings Conference Call and Webcast on May 7, 2026, at 8:00 a.m. Eastern TimeBEDFORD, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, May 7, 2026, to discuss its financial results and provide a business update for the first quarter of 2026. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 d
- INSIDERSEC Form 4 filed by Niedzwiecki Daniel4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.SCHEDULE 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)
LNTH FAQ
7 questionsWhat does Lantheus Holdings Inc. do?
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for...Where does LNTH stock trade?
Lantheus Holdings Inc. (LNTH) is listed on NASDAQ.What sector and industry is LNTH in?
Lantheus Holdings Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.When did Lantheus Holdings Inc. go public?
Lantheus Holdings Inc. (LNTH) completed its IPO in 2015.What are analysts saying about LNTH?
Lantheus Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from William Blair: Outperform on 2026-02-26.What companies are similar to LNTH?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), ORKA (Oruka Therapeutics Inc.), NNNN (Anbio Biotechnology), CLDX (Celldex Therapeutics Inc.). Compare LNTH side-by-side with any of them on Quantisnow.How can I track LNTH on Quantisnow?
Quantisnow aggregates Lantheus Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LNTH to receive live email and push alerts on every new disclosure.